Thromb Haemost 2007; 98(04): 705-706
DOI: 10.1160/TH07-08-0491
Editorial Focus
Schattauer GmbH

Editorial on “Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy” by Marcucci et al.

Tobias Geisler
1   Medizinische Klinik III, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
,
Meinrad Gawaz
1   Medizinische Klinik III, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
› Author Affiliations
Further Information

Publication History

Received 03 August 2007

Accepted 03 August 2007

Publication Date:
01 December 2017 (online)

 

 
  • References

  • 1 Marcucci R, Paniccia R, Antonucci E. et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy.. Thromb Haemost 2007; 98: 844-851.
  • 2 Yusuf S, Zhao F, Mehta SR. et al.; Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.. N Engl J Med 2001; 345: 494-502.
  • 3 Mehta SR, Yusuf S, Peters RJ. et al.; Clopidogrel in unstable angina to prevent recurrent events trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.. Lancet 2001; 358: 527-533.
  • 4 Geisler T, Gawaz M. Variable response to clopidogrel in patients with coronary artery disease.. Semin Thromb Hemost 2007; 33: 196-202.
  • 5 Muller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.. Thromb Haemost 2003; 89: 783-787.
  • 6 Cuisset T, Frere C, Quilici J. et al. High posttreatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.. J Thromb Haemost 2006; 4: 542-549.
  • 7 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.. Eur Heart J 2006; 27: 2420-2425.
  • 8 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.. J Am Coll Cardiol 2006; 48: 1742-1750.
  • 9 Geisler T, Kapp M, Göhring-Frischholz K. et al. Residual platelet activity is increased in Clopidogreland ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.. Heart 2007; epub ahead of print.
  • 10 Chen WH, Lee PY, Ng W. et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.. J Am Coll Cardiol 2004; 43: 1122-1126.
  • 11 Neumann FJ, Blasini R, Schmitt C. et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.. Circulation 1998; 98: 2695-2701.
  • 12 Neumann FJ, Hochholzer W, Pogatsa-Murray G. et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.. J Am Coll Cardiol 2001; 37: 1323-1328.
  • 13 Boersma E, Harrington RA, Moliterno DJ. et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials.. Lancet 2002; 359: 189-198.
  • 14 Ault KA, Cannon CP, Mitchell J. et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial.. J Am Coll Cardiol 1999; 33: 634-639.